HomeCompareSTBBF vs ABBV

STBBF vs ABBV: Dividend Comparison 2026

STBBF yields 3.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STBBF wins by $5.24M in total portfolio value· pulled ahead in Year 4
10 years
STBBF
STBBF
● Live price
3.00%
Share price
$97.45
Annual div
$2.93
5Y div CAGR
74.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.34M
Annual income
$4,275,651.80
Full STBBF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — STBBF vs ABBV

📍 STBBF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTBBFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STBBF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STBBF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STBBF
Annual income on $10K today (after 15% tax)
$255.40/yr
After 10yr DRIP, annual income (after tax)
$3,634,304.03/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, STBBF beats the other by $3,612,437.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STBBF + ABBV for your $10,000?

STBBF: 50%ABBV: 50%
100% ABBV50/50100% STBBF
Portfolio after 10yr
$2.72M
Annual income
$2,150,688.76/yr
Blended yield
78.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

STBBF
No analyst data
Altman Z
2.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STBBF buys
0
ABBV buys
0
No recent congressional trades found for STBBF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTBBFABBV
Forward yield3.00%3.12%
Annual dividend / share$2.93$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR74.5%40.6%
Portfolio after 10y$5.34M$104.7K
Annual income after 10y$4,275,651.80$25,725.73
Total dividends collected$5.23M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STBBF vs ABBV ($10,000, DRIP)

YearSTBBF PortfolioSTBBF Income/yrABBV PortfolioABBV Income/yrGap
1$11,224$524.32$11,559$438.51$335.00ABBV
2$12,970$959.78$13,494$640.86$524.00ABBV
3$15,686$1,808.65$15,951$945.97$265.00ABBV
4← crossover$20,352$3,567.42$19,152$1,413.89+$1.2KSTBBF
5$29,325$7,548.27$23,443$2,146.38+$5.9KSTBBF
6$49,115$17,737.40$29,391$3,321.96+$19.7KSTBBF
7$101,001$48,448.52$37,948$5,265.87+$63.1KSTBBF
8$270,554$162,482.62$50,795$8,596.74+$219.8KSTBBF
9$999,308$709,815.29$71,034$14,549.41+$928.3KSTBBF
10$5,344,912$4,275,651.80$104,715$25,725.73+$5.24MSTBBF

STBBF vs ABBV: Complete Analysis 2026

STBBFStock

Strabag SE, together with its subsidiaries, operates as a construction company. The company engages in the construction of road, rail, and canal bridges; commercial and industrial facilities; hydroelectric power plants, storage power plants, hydraulic power plants, concrete gravity dams, earth-filled and rock-filled embankment dams, reservoirs, external asphalt sealing, asphalt core sealing, thermal power plants, wind farms, and electrical substations; and administration buildings, events and cultural centers, museums, hospitals, rehabilitation centers, retirement and nursing homes, universities, schools, kindergartens, fire and rescue centers, and churches. It also constructs prefabricated elements, civil engineering projects, metal constructions, water environmental technologies, and housing projects. In addition, the company undertakes transportation infrastructure projects, including railway construction, construction material, sewer engineering, pipe and sewer construction, town planning and landscape architecture, paving, large surfaces, rock engineering and protective structures, ground engineering, sports and recreational facilities, road construction, earthworks, traffic engineering, and waterway construction projects. Further, it undertakes infrastructure development; engages in the operation, maintenance, and marketing of public-private partnerships projects; and provision of real estate development and tunneling services, as well as property and facility services, such as property management and corporate real estate solutions, area management, renting and letting, technical facility management and building management, infrastructural facility management, and industrial services. The company offers its services primarily in Europe, the Arabian Peninsula, Africa, Asia, and the Americas. Strabag SE was founded in 1835 and is headquartered in Villach, Austria.

Full STBBF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this STBBF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STBBF vs SCHDSTBBF vs JEPISTBBF vs OSTBBF vs KOSTBBF vs MAINSTBBF vs JNJSTBBF vs MRKSTBBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.